Literature DB >> 14563541

Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP.

Manuel Tancer1, Chris-Ellyn Johanson.   

Abstract

3,4-methylenedioxymethamphetamine (MDMA) is a widely used drug of abuse chemically related to both the amphetamines and mescaline. Laboratory animal studies have shown that MDMA is a potent re-uptake inhibitor and releaser of dopamine and serotonin. Although the subjective and physiological effects of MDMA have been compared to d-amphetamine in humans, no direct comparison with a serotonin releasing agent has been reported and reinforcing effects have not been evaluated. In this paper we report a direct comparison of the reinforcing, subjective, and physiological effects of MDMA (1 and 2 mg/kg) to d-amphetamine (10 and 20 mg), to metachlorophenylpiperazine (mCPP--a serotonin releasing agent (0.5 and 0.75 mg/kg)), and to placebo using a within-subject design in 12 volunteers with moderate MDMA experience. Both the high dose of d-amphetamine and MDMA showed significant reinforcing effects as indicated by high cross-over values on the multiple choice procedure compared to all other treatments. All three drugs showed dose-dependent changes in subjective effects whereas physiological effects were most pronounced for MDMA with almost no changes seen with mCPP. The subjective effects of MDMA were similar both to those of mCPP and d-amphetamine, suggesting that both dopamine and serotonin systems are involved in mediating these effects. In contrast, only the dopaminergic agents, d-amphetamine and MDMA, had reinforcing effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563541     DOI: 10.1016/s0376-8716(03)00172-8

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  57 in total

1.  Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Authors:  Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

2.  Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys.

Authors:  Jessica McClung; William Fantegrossi; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-23       Impact factor: 4.530

Review 3.  The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Authors:  Philip Kamilar-Britt; Gillinder Bedi
Journal:  Neurosci Biobehav Rev       Date:  2015-09-25       Impact factor: 8.989

4.  Do adolescent ecstasy users have different attitudes towards drugs when compared to marijuana users?

Authors:  Silvia S Martins; Carla L Storr; Pierre K Alexandre; Howard D Chilcoat
Journal:  Drug Alcohol Depend       Date:  2007-12-18       Impact factor: 4.492

Review 5.  The role of human drug self-administration procedures in the development of medications.

Authors:  S D Comer; J B Ashworth; R W Foltin; C E Johanson; J P Zacny; S L Walsh
Journal:  Drug Alcohol Depend       Date:  2008-04-24       Impact factor: 4.492

6.  Behavioral and neurochemical effects of repeated MDMA administration during late adolescence in the rat.

Authors:  Brittney M Cox; Mrudang M Shah; Teri Cichon; Manuel E Tancer; Matthew P Galloway; David M Thomas; Shane A Perrine
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-10-10       Impact factor: 5.067

7.  MDMA effects consistent across laboratories.

Authors:  Matthew G Kirkpatrick; Matthew J Baggott; John E Mendelson; Gantt P Galloway; Matthias E Liechti; Cédric M Hysek; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-03-15       Impact factor: 4.530

8.  The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.

Authors:  Manuel Tancer; Chris-Ellyn Johanson
Journal:  Psychopharmacology (Berl)       Date:  2006-10-18       Impact factor: 4.530

9.  Determining the subjective and physiological effects of BZP on human females.

Authors:  Joanne C Lin; Nisha Bangs; Heeseung Lee; Rob R Kydd; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2009-09-24       Impact factor: 4.530

10.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Authors:  M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.